Risk of severe infections in patients with triple-negative breast cancer treated with atezolizumab plus nab-paclitaxel: a real-world, postmarketing database study in Japan.

ABSTRACT:

Background

An increased risk of infection has been suggested for patients with triple-negative breast cancer (TNBC) treated with atezolizumab plus nab-paclitaxel based on the IMpassion130 trial.

Methods

This Japanese postmarketing study aimed to compare the incidence of severe infections in patients with TNBC treated with atezolizumab plus nab-paclitaxel versus nab-paclitaxel alone. Anonymized patient records regarding medical claims and laboratory tests were extracted from the Japanese Medical Data Vision database. Patients with a drug index date of November 27, 2019,-May 31, 2022, were included in the analysis. Based on the published literature, severe infections were declared when a patient had a confirmed diagnosis of infection, a hospitalization record, infection as the

SUBMITTER: Yuri A 

PROVIDER: S-EPMC12644192 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature